NCT00320346View on ClinicalTrials.gov

Phase II Study of Pandemic Influenza Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

July 31, 2006

Study Completion Date

September 30, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

Pandemic Influenza Vaccine

Trial Locations (3)

3052

Murdoch Childrens Research Institute, Melbourne

Unknown

CMAX, a division of IDT Australia, Adelaide

Princess Margaret Hospital for Children, Perth

All Listed Sponsors
lead

Seqirus

INDUSTRY

NCT00320346 - Phase II Study of Pandemic Influenza Vaccine | Biotech Hunter | Biotech Hunter